VIATRIS INC. O.N. Logo
US92556V1061
A2QAME
VTRS

VIATRIS INC. O.N.

Caricamento quotazioni...

Previsioni

Il prezzo obiettivo medio degli analisti è 19,22 € (+4,29%). La mediana è 19,10 € (+3,64%).

Acquista
  5
Mantieni
  7
Vendi
  1

Discussioni nella community

  • Fehler: Dieses Portfolio ist privat

    PN Parqet Nutzer I in Schnack

    0 45
  • Spin-Off

    user_9c1f0a user_9c1f0a I in Schnack

    1 7

  • Viatris raises guidance after Q2 growth and gains FDA approval for contraceptive patch

    Viatris reported Q2 revenue up about 4.9% year over year and management raised fiscal 2026 guidance across key metrics. Billionaire-led funds held stakes in the stock as it traded near $16, up ~33% year-to-date. The FDA approved the once-weekly Gwyn Lo contraceptive patch, a fast-acting meloxicam formulation is under review and two late-stage trials (selatogrel and cenerimod) will report in early fiscal 2027. Valuation looks attractive (forward non-GAAP P/E ~6.6, EV/EBITDA ~7) but tariff risk and looming changes to generic exemptions in 2028 pose material downside for its import-reliant portfolio. » Altro su finance.yahoo.com


  • Viatris beats Q2 expectations and raises full-year outlook

    Viatris reported adjusted EPS of $0.69 for Q2 2026 (expectation $0.61) and revenue of $3.76 billion versus expected $3.67 billion, and subsequently raised its full-year guidance. Free cash flow and margins improved; adjusted EBITDA was $1.2 billion and gross margin rose to 57.5%. Debt fell to about 2.9x. The stock dipped slightly premarket as investors weighed potential H2 risks such as a new procurement policy in China, production interruptions in Nashik and intensified competition. » Altro su de.investing.com


  • Viatris receives FDA approval for once-weekly contraceptive patch Gwyn Lo

    The FDA has approved Gwyn Lo, a once-weekly contraceptive patch from Viatris containing norelgestromin and ethinylestradiol. The patch is intended for women of childbearing potential with a BMI under 30 kg/m² and delivers 220 mcg norelgestromin and 20 mcg ethinylestradiol per day. Approval was based on the Phase III Luminous study, which showed a Pearl Index of 4.14 and complete detachment of only 1.3% of applied systems. Common side effects included application-site reactions, irregular and heavy withdrawal bleeding, and nausea; Gwyn Lo is contraindicated in smokers over 35 and in women with BMI ≥30 kg/m². Viatris expects to launch the product later this year. » Altro su de.investing.com


  • Viatris hits 52‑week high of $17.68 after strong quarterly results and Phase‑3 success

    Viatris shares rose to a 52‑week high of $17.68, driven by strong price performance (+90.82% year‑to‑date) and a market capitalization of $20.6 billion. The company beat Q1‑2026 expectations with adjusted EPS of $0.59 (consensus $0.51) and revenue of $3.52 billion. Viatris also reported positive Phase‑3 results for the IgAN drug VR‑205 in Japan, and the FDA has accepted the approval filing for a rapid‑acting meloxicam formulation (PDUFA date 27.12.2026). InvestingPro rates the stock as undervalued; management has executed aggressive buybacks and expects to be profitable this year. » Altro su de.investing.com


  • Viatris hits 52-week high at $17.53 after strong results and study successes

    Viatris shares rose to a new 52-week high of $17.53; market capitalization stands at $20.26 billion. Year-to-date the stock has climbed 41% and is up 94% over the past year. Viatris beat Q1 2026 analyst expectations with adjusted EPS of $0.59 and revenue of $3.52 billion. The company also reported positive Phase‑3 results for VR‑205 in Japan and the FDA has accepted the approval pathway for MR‑107A‑02 (PDUFA date 27.12.2026). According to InvestingPro, the calculated fair value indicates further upside potential. » Altro su de.investing.com

Nel 2026, VIATRIS INC. O.N. ha già distribuito 0,30 € di dividendi. L'ultimo pagamento è avvenuto a settembre.

Dati finanziari dell'azienda

Nell'ultimo trimestre, VIATRIS INC. O.N. ha registrato ricavi pari a 3,31 Mld € e un utile netto di -287,19 Mln €
(EUR) settembre 2026
YoY
Ricavi 3,31 Mld 3,32%
Utile lordo 1,27 Mld 7,58%
Utile netto -287,19 Mln 162,89%
EBITDA 827,67 Mln 21,38%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
21,63 Mld €
Numero di azioni
1,15 Mld
Massimo/minimo a 52 settimane
19,29 € - 9,23 €
Rendimento da dividendo
2,19%
Dividendi TTM
0,42 €
Prossimo dividendo
0,11 €
Beta
0,87
Rapporto P/E
-39,13
Rapporto PEG
1,11
Rapporto P/B
1,74
Rapporto P/S
1,61

Profilo aziendale

Viatris Inc. opera come società sanitaria a livello mondiale. La società opera in quattro segmenti: Developed Markets, Greater China, JANZ ed Emerging Markets. Offre farmaci di marca con prescrizione, farmaci generici, farmaci generici complessi, biosimilari e principi attivi farmaceutici (API). La società offre farmaci in diverse aree terapeutiche, tra cui malattie non trasmissibili e malattie infettive; biosimilari nelle aree di oncologia, immunologia, endocrinologia, oftalmologia e dermatologia; e API per gli antibatterici, gli agenti del sistema nervoso centrale, gli antistaminici/antiasmatici, il cardiovascolare, gli antivirali, gli antidiabetici, gli antimicotici e gli inibitori di pompa protonica, nonché servizi di supporto, quali cliniche diagnostiche, seminari educativi e strumenti digitali per aiutare i pazienti a gestire meglio la propria salute. Fornisce i propri medicinali sotto forma di dosi solide orali, iniettabili, forme farmaceutiche complesse e API a farmacie al dettaglio e strutture di farmacia, grossisti e distributori, payer, assicuratori e governi, e istituzioni. La società distribuisce i propri prodotti tramite grossisti/distributori farmaceutici, farmacie al dettaglio, farmacie istituzionali, farmacie di vendita per corrispondenza ed e-commerce e farmacie specializzate. Vende i propri prodotti con i marchi Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, auto-iniettore EpiPen, Fraxiparine e Yupelri; Norvasc e Viagra; AMITIZA, Lipacreon ed Effexor; e Celebrex e ARV, e offre franchising di biosimilari, tra cui Fulphila, Ogivri, Hulio e SEMGLEE. La società ha accordi di collaborazione e licenza con Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; e Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. è stata fondata nel 1961 e ha sede a Canonsburg, Pennsylvania.

Nome
VIATRIS INC. O.N.
CEO
Scott Andrew Smith
Sede centrale Canonsburg, pa
Stati Uniti
Sito web
Settore
Sanità
Industria
Prodotti farmaceutici
Quotazione in borsa
17/03/1980
Dipendenti 30.000

Simboli di borsa

Borsa Simbolo
NASDAQ
VTRS
XETRA
VIA.DE
Frankfurt
VIA.F
Düsseldorf
VIA.DU
Hamburg
VIA.HM
Milan
1VTRS.MI
London
0A5V.L
München
VIA.MU
Wien
VTRS.VI
SIX
VTRS.SW
🍪

Parqet  usa i cookie. Scopri di più